BioAffinity Technologies, Number Of Shares Shorted vs. Shares Owned By Insiders
| BIAF Stock | USD 0.58 0.07 10.77% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.67 | 0.36 |
|
|
For BioAffinity Technologies, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioAffinity Technologies, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well bioAffinity Technologies, utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioAffinity Technologies,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of bioAffinity Technologies, over time as well as its relative position and ranking within its peers.
BioAffinity |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share | Quarterly Revenue Growth 120.474 | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
bioAffinity Technologies, Shares Owned By Insiders vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioAffinity Technologies,'s current stock value. Our valuation model uses many indicators to compare BioAffinity Technologies, value to that of its competitors to determine the firm's financial worth. bioAffinity Technologies, is rated third in number of shares shorted category among its peers. It is rated second in shares owned by insiders category among its peers . The ratio of Number Of Shares Shorted to Shares Owned By Insiders for bioAffinity Technologies, is about 13,428 . Comparative valuation analysis is a catch-all technique that is used if you cannot value BioAffinity Technologies, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.BioAffinity Shares Owned By Insiders vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
BioAffinity Technologies, |
| = | 396.79 K |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
BioAffinity Technologies, |
| = | 29.55 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
BioAffinity Shares Owned By Insiders Comparison
BioAffinity Technologies, is currently under evaluation in shares owned by insiders category among its peers.
BioAffinity Technologies, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioAffinity Technologies,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioAffinity Technologies, will eventually generate negative long term returns. The profitability progress is the general direction of BioAffinity Technologies,'s change in net profit over the period of time. It can combine multiple indicators of BioAffinity Technologies,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -3.6 M | -3.8 M | |
| Operating Income | -7.2 M | -6.8 M | |
| Income Before Tax | -7.1 M | -7.5 M | |
| Total Other Income Expense Net | 65.8 K | 69.1 K | |
| Net Loss | -7.1 M | -7.5 M | |
| Income Tax Expense | 24.1 K | 25.3 K | |
| Net Interest Income | 42.6 K | 44.7 K | |
| Interest Income | 170.7 K | 179.2 K | |
| Net Loss | -6.5 M | -6.8 M | |
| Net Loss | -7.3 M | -7.6 M | |
| Change To Netincome | 2.8 M | 3.1 M | |
| Net Loss | (1.04) | (1.10) | |
| Income Quality | 0.68 | 0.42 | |
| Net Income Per E B T | 0.90 | 0.80 |
BioAffinity Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioAffinity Technologies,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioAffinity Technologies, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioAffinity Technologies,'s important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in BioAffinity Technologies, without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Transaction History Now
Transaction HistoryView history of all your transactions and understand their impact on performance |
| All Next | Launch Module |
Use Investing Themes to Complement your BioAffinity Technologies, position
In addition to having BioAffinity Technologies, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Losers Thematic Idea Now
Latest Losers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Losers theme has 160 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Losers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
To fully project BioAffinity Technologies,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of bioAffinity Technologies, at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioAffinity Technologies,'s income statement, its balance sheet, and the statement of cash flows.